Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAT2 | Q10469 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8264324 | 0.92 | CHRM5 (0.47) | MGAT2DGAT2ESR2NR1H2MAPT | |
| SCHEMBL1752020 | 0.89 | MGAT2 (0.48) | MGAT2DGAT2ESR2NR1H2MAPT | |
| SCHEMBL8262901 | 0.89 | MGAT2 (0.39) | MGAT2DGAT2ESR2NR1H2USP30 | |
| SCHEMBL8264160 | 0.88 | USP30 (0.47) | ESR2NR1H2USP30ADORA1MAPK1 | |
| SCHEMBL8263465 | 0.87 | USP30 (0.48) | MGAT2DGAT2MAPTKDM4EUSP30 | |
| SCHEMBL951850 | 0.87 | ESR2 (0.48) | ESR2NR1H2USP30ADORA1MAPK1 | |
| SCHEMBL13490875 | 0.83 | MGAT2 (0.42) | MGAT2DGAT2ESR2MAPTCHRM5 | |
| SCHEMBL8263481 | 0.82 | MEN1 (0.43) | MGAT2DGAT2ESR2NR1H2USP30 | |
| SCHEMBL8264279 | 0.82 | CHRM2 (0.48) | ESR2NR1H2USP30MAPK1CHRM5 | |
| SCHEMBL8264338 | 0.82 | CHRM5 (0.46) | MGAT2DGAT2ESR2NR1H2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| WO-2006074924-A1 | 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | MGAT2 2203/4885DGAT2 4763/4885ESR2 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.